Lopez M, Natali M, Di Lauro L, Vici P, Pignatti F, Carpano S
Division of Medical Oncology II, Regina Elena Institute for Cancer Research, Rome, Italy.
Cancer. 1993 Jul 15;72(2):502-5. doi: 10.1002/1097-0142(19930715)72:2<502::aid-cncr2820720228>3.0.co;2-1.
Male breast cancer (MBC) is considered an androgen-dependent tumor, and as in prostatic cancer, responses have been reported with use of antiandrogens or gonadotropin-releasing hormone analogs. Thus, it is reasonable to postulate that better results could be achieved by combining these two agents.
Eleven men with recurrent or progressive carcinoma of the breast have been treated with buserelin 1500 micrograms subcutaneously daily in the first week and 600 micrograms daily subsequently and cyproterone acetate (CPA) 100 mg twice a day orally starting 24 hours before the first dose of buserelin.
Objective responses have been observed in seven patients with a median duration of 11.5 months (range, 9-24+ months). Responses were not correlated to the dominant site of disease. Three patients had stable disease lasting 5 months. Median survival was 18.5 months. Side effects primarily were decrease or loss of libido, impotence, and hot flushes.
Total androgen blockade with buserelin and CPA seems effective in the treatment of patients with advanced cancer of the male breast, but its superiority over standard androgen suppression remains to be demonstrated.
男性乳腺癌（MBC）被认为是一种雄激素依赖性肿瘤，与前列腺癌一样，使用抗雄激素药物或促性腺激素释放激素类似物已报道有疗效。因此，推测联合使用这两种药物可能会取得更好的效果是合理的。
11例复发性或进展性男性乳腺癌患者接受治疗，第一周每天皮下注射布舍瑞林1500微克，随后每天600微克，醋酸环丙孕酮（CPA）在第一剂布舍瑞林前24小时开始每天口服2次，每次100毫克。
7例患者观察到客观缓解，中位缓解持续时间为11.5个月（范围9 - 24 +个月）。缓解与疾病的主要部位无关。3例患者疾病稳定持续5个月。中位生存期为18.5个月。副作用主要是性欲减退或丧失、阳痿和潮热。
布舍瑞林和CPA的全雄激素阻断疗法似乎对晚期男性乳腺癌患者有效，但其相对于标准雄激素抑制的优越性仍有待证明。
